David Rosmarin, Dermatology Meeting News 2022: Ruxolitinib Cream Monotherapy for the Treatment of Vitiligo
We were delighted to talk with Dr. David Rosmarin (Tufts Medical Center, Boston, MA, USA) to discuss the efficacy and safety findings of the TRuE-V1 and TRuE-V2 studies, investigating ruxolitinib cream monotherapy for the treatment of vitiligo.
The abstract ‘Efficacy and Safety of Ruxolitinib Cream Monotherapy for the Treatment of Vitiligo: Results From Two 52-Week Phase 3 Studies’ was presented at AAD-VMX 2022, 25-29 March.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the AAD. Â
Questions
- What is the rationale for the use of ruxolitinib cream in the treatment of vitiligo? (0:13)
- What were the aims, design and eligibility criteria of the TRuE-V1 and TRuE-V2 studies? (0:45)
- What were the efficacy and safety findings of these studies? (2:00)
- If approved, what will be the impact of ruxolitinib cream on the treatment of patients with vitiligo? (3:16)
- Which patients are most likely to respond to this treatment? (3:40)
- What future studies are planned? (4:24)
Disclosures: David Rosmarin discloses consulting for AbbVie, Abcuro, AltruBio, Arena, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Incyte, Janssen, Kyowa Kirin, Lilly, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceuticals, UCB, VielaBio; grant/ research support from AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Dermira, Galderma, Incyte, Janssen, Lilly, Merck, Novartis, Pfizer, and Regeneron Pharmaceuticals; and participating in speaker’s bureaus for AbbVie, Amgen, Bristol Meyers Squibb, Celgene, Incyte, Janssen, Lilly, Novartis, Pfizer, Regeneron Pharmaceuticals Inc., and Sanofi.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAD-VMX annual meeting 2022.